(PRWEB) March 12, 2013
Xarelto is an anticoagulant that is manufactured by the Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Approved by The U.S. Food and Drug Administration in just 2011, the drug was intended to act as a blood thinner to help prevent blood clots and deep-vein thrombosis. However, in the short amount of time that drug has been prescribed in the U.S. market there have been numerous reports that the drug is allegedly causing side effects such as moderate to severe internal bleeding, cerebral hemorrhages, and stroke by worsening the conditions it was meant to combat.
Xarelto now joins a group of other blood thinning drugs, such as Pradaxa and Eliquis that were developed as a substitute to the ‘warfarin.’ Warfarin was an anticoagulant that was developed in the 1940s and approved for medical usage in 1954. Despite its popularity, the drug was linked to worsening symptoms of hemorrhaging and internal bleeding. The growing need to find an alternative to it resulted in the rise of Pradaxa, Eliquis, and Xarelto.
However, as the popularity for these drugs increased, so too did the reports of severe side effects and worsening of symptoms associated with them. As this occurred, experts across the medical industry expressed concerns as to whether Xarelto use, which was intended to be warfarin substitute, offered any benefit over the dangerous drug it was designed to replace. A 2011 study published in the New England Journal of Medicine found that prescribing doctors could not conclusively determine any effectiveness Xarelto has over Warfarin(i). Following that up in 2012, an FDA advisory panel was formed where the members stressed the severity of Xarelto’s side effects. One panel member, Dr. Nissen, who is chairman of the Cleveland Clinic Foundation, voted to deny just the use of Xarelto because there was only “marginal evidence” of a benefit of Xarelto usage(ii).
Moreover, even standing alone and without the comparison to warfarin, the side effects from Xarelto usage are alarming. Reuters reported that after continued reports of internal bleeding and worsening of blood clots, Xarelto’s manufacturer conducted an internal study and found that patients using Xarelto were four times as likely to suffer severe internal bleeding after just 25 days than users of similar products, such as Sanofi-Aventis’, Lovenox(iii). As reported by the Huffington Post, in 2012, the Institute for Safe Medication Practices studied the FDA’s adverse event reporting system for “serious, disabling or fatal injury” and found that Xarelto was at the top of the category with 356 reports – half of those being worsening blood clots(iv). In light of all of this, the FDA has required Xarelto to contain a “black-box” warning on the label; the strongest warning the FDA can require(v).
Concern about the drugs adverse side effects has not been limited chain linking the manufacturer to the patients using it – now other companies are stepping in to find a way to combat this drug’s side effects. This past week, Reuters reported that the German drug manufacturer Bayer AG is teaming up with U.S. partner Portola Pharmaceuticals to conduct a study of numerous drugs in an effort to reverse the amount of and severity Xarelto’s side effects(vi).
If you or a loved one has been injured or suffered any alleged Xarelto side effects, you may be entitled to compensation and should consider filing a Xarelto claim or lawsuit. Working with some of the leading defective drug and Xarelto attorneys in the nation, the attorneys at d’Oliveira & Associates can help ensure that you are afforded the legal representation you deserve and promise you a “No Win, No Fee Promise.” If you have a Xarelto claim or lawsuit, the attorneys at d’Oliveira & Associates guarantee that you will not be charged until you receive an award.
Please contact the law offices of d’Oliveira & Associates at 1-800-992-6878 or fill out a contact form for a free legal consultation.